Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...
We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...
Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...
StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...
BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...
Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...
RMD recently launched its home sleep apnea test, NightOwl, across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT), designed to offer healthcare providers a simplified, ...
People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...
NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its ...
Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...
ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.